Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1992-02-19
1994-05-10
Brown, Johnnie R.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
536 277, A61K 3170, C07H 19173
Patent
active
053107322
ABSTRACT:
Novel adenine derivatives whose structures are represented by Formula I, are disclosed, as are methods of using those compounds and others of Formula II to treat monocyte-mediated disorders such as rheumatoid arthritis and multiple sclerosis.
REFERENCES:
patent: 3472838 (1969-10-01), Hanessian
patent: 3539559 (1970-11-01), Greenberg et al.
patent: 4751221 (1988-06-01), Watanabe et al.
patent: 4826823 (1989-05-01), Cook et al.
patent: 5106837 (1992-04-01), Carson et al.
Carrera et al., "Potent Toxicity of 2-Chlorodeoxyadenosine Toward Human Monocytes In Vitro and In Vivo. A Novel Approach to Immunosuppressive Therapy," J. Clinical Invest., 86, 1480-1488 (1990).
Priebe et al., "Selective Modulation of Antibody Response and Natural Killer Cell Activity by Purine Nucleoside Analogues," Cancer Research, 48(17), 4799-4803 (1988).
Montgomery et al., "9-(2-Deoxy-2-fluoro-.beta.-D-arabinofuranosyl)guanine: A Metabolically Stable Cytotoxic Analogue of 2'-Deoxyguanosine," J. Med. Chem., 29, 2389-2392 (1986).
Matsuda et al., "Synthesis of a Mutagenic Nucleoside, 2'-Deoxy-2-(p-nitrophenyl)-adenosine," presented at the 14th Symposium on Nucleic Acids Chemistry, Nucleic Acids, Res. Symposium Ser., No. 17, Tokushima, Japan, pp. 141-143 (Nov. 1, 1986).
Christensen et al., "Synthesis and Biological Activity of Selected 2,6-Disubstituted-(2-deoxy-.alpha.-and .beta.-D-erythro-pentofuranosyl)purines," J. Med. Chem., 15(7), 735-739 (1972).
Khan et al., "Elucidation of the Mechanism of Selective Inhibition of Mammalian DNA Polymerase Alpha by 2-butylanilinopurines: Development of Characterization of 2-(p-n-butylanilino)adenine and Its Deoxyribonucleotides," Nucleic Acids Res., 13(17), 6331-6342 (1985).
Parsons et al., "Selective Toxicity of Deoxyadenosine Analogues in Human Melanoma Cell Lines," Biochem. Pharm., 35(22), 4025-4029 (1986).
"Protection de la Liason Glycosidique en Serie Desoxy-2'Adenosine," Tett. Lett. 24(1), 53-56 (1983).
Scott, Supplemental European Patent Office Search Report for PCT/US89/01088, Nov. 20, 1990.
Kochetkov et al., Organic Chemistry of Nucleic Acids, Part B, Plenum Press, New York, 1972, p. 335.
Singleton et al., Dictionary of Microbiology and Molecular Biology, 2nd Ed., John Wiley & Sons, New York, 1987, pp. 513, 562 and 563.
Berkow et al. eds., The Merck Manual of Diagnosis and Therapy, 14th Ed., Merck & Co., Inc., 1982, Rahway, N.J., pp. 1083-1084.
Carrera Carlos J.
Carson Dennis A.
Brown Johnnie R.
Crane L. Eric
The Scripps Research Institute
LandOfFree
2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthrit does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthrit, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthrit will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2412370